(Q37681047)

English

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

scientific article published on 10 February 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

1 reference

based on heuristic

inferred from title

2

object named as

William Pao

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

author name string

Jennifer L Clarke

1

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Nian Wu

3

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Vincent A Miller

4

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Andrew B Lassman

5

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

publication date

10 February 2010

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

99

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

283-286

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

https://scigraph.springernature.com/pub.10.1007/s11060-010-0128-6

0 references

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3973736

23 August 2017

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3973736

23 August 2017

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3973736

23 August 2017

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3973736

23 August 2017

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3973736

14 September 2017

A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3973736

25 June 2018

Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3973736

1 September 2018

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3973736

1 September 2018

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3973736

1 September 2018

Identifiers

10.1007/S11060-010-0128-6

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

release_doq3qukvuzaxxm27fqujxg3c7m

1 reference

https://api.fatcat.wiki/v0/release/doq3qukvuzaxxm27fqujxg3c7m

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37681047&oldid=2103114633"